In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
スポンサーリンク
概要
- 論文の詳細を見る
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The definitive publisher-authenticated version The Journal of antimicrobial chemotherapy, 62(6), pp.1326-1331; 2008 is available online at: http://jac.oxfordjournals.org/cgi/content/abstract/62/6/1326 .OBJECTIVES: Tomopenem (CS-023) is a novel parenteral carbapenem with broad-spectrum activity against Gram-positive and -negative bacteria, as well as potent activity against drug-resistant pathogens, including penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. We compared the in vivo activity of tomopenem and that of meropenem in a chronic lower respiratory infection mouse model of P. aeruginosa. METHODS: Mice with chronic airway infection by P. aeruginosa were treated with saline (as the control, twice daily), tomopenem (100 mg/kg, twice daily) or meropenem (100 mg/kg, twice daily) for 7 days. After treatment, the number of viable bacteria in lungs and histopathological findings were analysed. The pharmacokinetics of tomopenem and meropenem were also analysed after initial treatment. RESULTS: The number of viable bacteria in lungs treated with saline, tomopenem or meropenem was 4.21 +/- 1.28, 2.91 +/- 0.87 and 3.01 +/- 1.00 log(10) cfu/lung (mean +/- SEM), respectively (P < 0.05, control versus tomopenem- or meropenem-treated groups). In the histopathological examination of lung specimens, the control group had the features of chronic bronchial infection; however, tomopenem- and meropenem-treated groups had fewer inflammatory cells compared with the control group. The pharmacokinetic parameter of % time above MIC for tomopenem and meropenem was 16% and 17% in sera and 15% and 18% in lungs, respectively. CONCLUSIONS: Tomopenem significantly reduced the number of viable bacteria in a murine model of chronic airway infection by P. aeruginosa, compared with the control. Considering the longer half-life of tomopenem in humans compared with most other carbapenems, tomopenem treatment of chronic airway infection with P. aeruginosa is expected to be efficacious.
論文 | ランダム
- P1-4 全身性エリテマトーデスとNK/T細胞リンパ腫治療後に発症した気管支アミロイドーシスの一例(症例1,ポスター1,第31回日本呼吸器内視鏡学会学術集会)
- Y8-2 気管支鏡検査で診断されたニューモシスチス肺炎(PCP)の検討(BAL,TBLBの診断的意義,要望演題8,第31回日本呼吸器内視鏡学会学術集会)
- Y7-6 モザイキング技術による中枢気道の気管支鏡画像解析(気道再生及び基礎的研究,要望演題7,第31回日本呼吸器内視鏡学会学術集会)
- Y4-3 気管支鏡挿入支援システム(VTR・診断,要望演題4,第31回日本呼吸器内視鏡学会学術集会)
- S1-4 Virtual Bronchoscopic Navigationシステムによる肺末梢病変の診断(内視鏡による新しい診断方法(末梢部病変),シンポジウム1,第31回日本呼吸器内視鏡学会学術集会)